With the development race for Covid-19 vaccine reached a crucial stage by testing many potential vaccines in the last stage studies, the pricing of vaccines has become increasingly scrutinized.
“We will be responsible for the price well below the value of (the vaccine) during the epidemic period,” Stefan Bansel, CEO of Moderna said in a conference call, adding that the larger-sized contracts the vaccine will have a lower price.
Last month, the US government signed an agreement to buy a trial vaccine developed by Pfizer and BioNetech, with the aim of providing a sufficient vaccine to vaccinate 50 million Americans for about $ 40 per person. Moderna’s dual-dose vaccine regimen will cost between $ 64 and $ 74 per person.
Moderna has received about $ 1 billion from the US government under a plan to accelerate vaccine development. It has not yet concluded an agreement to supply the vaccine to the United States.
The company said today that it is in talks with several countries to sign agreements to supply its vaccine, adding that it has already received about $ 400 million in advance contracts for supply contracts.
Moderna’s shares fell by five percent in early trading, on Wednesday.